| Year |
Citation |
Score |
| 2017 |
Dogan T, Gnad F, Chan J, Phu L, Young A, Chen MJ, Doll S, Stokes MP, Belvin M, Friedman LS, Kirkpatrick DS, Hoeflich KP, Hatzivassiliou G. Role of the E3 ubiquitin ligase RNF157 as a novel downstream effector linking PI3K and MAPK signaling to the cell cycle. The Journal of Biological Chemistry. PMID 28655764 DOI: 10.1074/Jbc.M117.792754 |
0.354 |
|
| 2013 |
Kirkpatrick DS, Bustos DJ, Dogan T, Chan J, Phu L, Young A, Friedman LS, Belvin M, Song Q, Bakalarski CE, Hoeflich KP. Phosphoproteomic characterization of DNA damage response in melanoma cells following MEK/PI3K dual inhibition. Proceedings of the National Academy of Sciences of the United States of America. 110: 19426-31. PMID 24218548 DOI: 10.1073/Pnas.1309473110 |
0.342 |
|
| 2011 |
Ong CC, Jubb AM, Zhou W, Haverty PM, Harris AL, Belvin M, Friedman LS, Koeppen H, Hoeflich KP. p21-activated kinase 1: PAK'ed with potential. Oncotarget. 2: 491-6. PMID 21653999 DOI: 10.18632/Oncotarget.271 |
0.3 |
|
| 2011 |
Ong CC, Jubb AM, Haverty PM, Zhou W, Tran V, Truong T, Turley H, O'Brien T, Vucic D, Harris AL, Belvin M, Friedman LS, Blackwood EM, Koeppen H, Hoeflich KP. Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells. Proceedings of the National Academy of Sciences of the United States of America. 108: 7177-82. PMID 21482786 DOI: 10.1073/Pnas.1103350108 |
0.329 |
|
| 2010 |
Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, Ludlam MJ, Stokoe D, Gloor SL, Vigers G, Morales T, Aliagas I, Liu B, Sideris S, Hoeflich KP, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature. 464: 431-5. PMID 20130576 DOI: 10.1038/nature08833 |
0.334 |
|
| 2010 |
Hoeflich K, Ong C, Jubb A, Haverty P, Truong T, Harris A, Belvin M, Friedman L, Blackwood E, Koeppen H. 343 Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of squamous NSCLC cells European Journal of Cancer Supplements. 8: 109. DOI: 10.1016/S1359-6349(10)72050-4 |
0.32 |
|
| 2009 |
Hoeflich KP, Herter S, Tien J, Wong L, Berry L, Chan J, O'Brien C, Modrusan Z, Seshagiri S, Lackner M, Stern H, Choo E, Murray L, Friedman LS, Belvin M. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression. Cancer Research. 69: 3042-51. PMID 19276360 DOI: 10.1158/0008-5472.CAN-08-3563 |
0.358 |
|
| 2008 |
Degtyarev M, De Mazière A, Orr C, Lin J, Lee BB, Tien JY, Prior WW, van Dijk S, Wu H, Gray DC, Davis DP, Stern HM, Murray LJ, Hoeflich KP, Klumperman J, et al. Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents. The Journal of Cell Biology. 183: 101-16. PMID 18838554 DOI: 10.1083/Jcb.200801099 |
0.312 |
|
| 2006 |
Hoeflich KP, Eby MT, Forrest WF, Gray DC, Tien JY, Stern HM, Murray LJ, Davis DP, Modrusan Z, Seshagiri S. Regulation of ERK3/MAPK6 expression by BRAF. International Journal of Oncology. 29: 839-49. PMID 16964379 DOI: 10.3892/Ijo.29.4.839 |
0.359 |
|
| 2004 |
Hoeflich KP, Ikura M. Radixin: cytoskeletal adopter and signaling protein. The International Journal of Biochemistry & Cell Biology. 36: 2131-6. PMID 15313460 DOI: 10.1016/J.Biocel.2003.11.018 |
0.338 |
|
| 2003 |
Zhang Y, Zhang J, Hoeflich KP, Ikura M, Qing G, Inouye M. MazF cleaves cellular mRNAs specifically at ACA to block protein synthesis in Escherichia coli. Molecular Cell. 12: 913-23. PMID 14580342 DOI: 10.1016/S1097-2765(03)00402-7 |
0.308 |
|
| 2003 |
Hoeflich KP, Tsukita S, Hicks L, Kay CM, Tsukita S, Ikura M. Insights into a single rod-like helix in activated radixin required for membrane-cytoskeletal cross-linking. Biochemistry. 42: 11634-41. PMID 14529273 DOI: 10.1021/Bi0350497 |
0.331 |
|
| 2001 |
Ali A, Hoeflich KP, Woodgett JR. Glycogen synthase kinase-3: properties, functions, and regulation. Chemical Reviews. 101: 2527-40. PMID 11749387 DOI: 10.1021/Cr000110O |
0.45 |
|
| 2001 |
Hoeflich KP, Woodgett JR. Chapter 13 Mitogen-activated protein kinases and stress Cell and Molecular Response to Stress. 2: 175-193. DOI: 10.1016/S1568-1254(01)80015-2 |
0.463 |
|
| 2000 |
Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin O, Woodgett JR. Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature. 406: 86-90. PMID 10894547 DOI: 10.1038/35017574 |
0.48 |
|
| 1999 |
Hoeflich KP, Yeh WC, Yao Z, Mak TW, Woodgett JR. Mediation of TNF receptor-associated factor effector functions by apoptosis signal-regulating kinase-1 (ASK1). Oncogene. 18: 5814-20. PMID 10523862 DOI: 10.1038/Sj.Onc.1202975 |
0.551 |
|
| 1999 |
Cannons JL, Hoeflich KP, Woodgett JR, Watts TH. Role of the stress kinase pathway in signaling via the T cell costimulatory receptor 4-1BB. Journal of Immunology (Baltimore, Md. : 1950). 163: 2990-8. PMID 10477561 |
0.463 |
|
| 1999 |
Lee ST, Hoeflich KP, Wasfy GW, Woodgett JR, Leber B, Andrews DW, Hedley DW, Penn LZ. Bcl-2 targeted to the endoplasmic reticulum can inhibit apoptosis induced by Myc but not etoposide in Rat-1 fibroblasts. Oncogene. 18: 3520-8. PMID 10376530 DOI: 10.1038/Sj.Onc.1202716 |
0.454 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2012 |
Hoeflich KP, Merchant M, Orr C, Chan J, Den Otter D, Berry L, Kasman I, Koeppen H, Rice K, Yang NY, Engst S, Johnston S, Friedman LS, Belvin M. Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition. Cancer Research. 72: 210-9. PMID 22084396 DOI: 10.1158/0008-5472.CAN-11-1515 |
0.299 |
|
| 2013 |
Rudolph J, Crawford JJ, Hoeflich KP, Chernoff J. p21-activated kinase inhibitors. The Enzymes. 34: 157-80. PMID 25034104 DOI: 10.1016/B978-0-12-420146-0.00007-X |
0.292 |
|
| 2009 |
Sos ML, Fischer S, Ullrich R, Peifer M, Heuckmann JM, Koker M, Heynck S, Stückrath I, Weiss J, Fischer F, Michel K, Goel A, Regales L, Politi KA, Perera S, ... ... Hoeflich KP, et al. Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proceedings of the National Academy of Sciences of the United States of America. 106: 18351-6. PMID 19805051 DOI: 10.1073/Pnas.0907325106 |
0.29 |
|
| 2013 |
Ong CC, Jubb AM, Jakubiak D, Zhou W, Rudolph J, Haverty PM, Kowanetz M, Yan Y, Tremayne J, Lisle R, Harris AL, Friedman LS, Belvin M, Middleton MR, Blackwood EM, ... ... Hoeflich KP, et al. P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanoma. Journal of the National Cancer Institute. 105: 606-7. PMID 23535073 DOI: 10.1093/Jnci/Djt054 |
0.286 |
|
| 2015 |
Chow HY, Dong B, Duron SG, Campbell DA, Ong CC, Hoeflich KP, Chang LS, Welling DB, Yang ZJ, Chernoff J. Group I Paks as therapeutic targets in NF2-deficient meningioma. Oncotarget. 6: 1981-94. PMID 25596744 DOI: 10.18632/Oncotarget.2810 |
0.283 |
|
| 2004 |
Zheng L, Hoeflich KP, Elsby LM, Ghosh M, Roberts SG, Ikura M. FRET evidence for a conformational change in TFIIB upon TBP-DNA binding. European Journal of Biochemistry / Febs. 271: 792-800. PMID 14764096 DOI: 10.1111/J.1432-1033.2004.03983.X |
0.279 |
|
| 2002 |
Hoeflich KP, Ikura M. Calmodulin in action: diversity in target recognition and activation mechanisms. Cell. 108: 739-42. PMID 11955428 DOI: 10.1016/S0092-8674(02)00682-7 |
0.274 |
|
| 2015 |
Ong CC, Gierke S, Pitt C, Sagolla M, Cheng CK, Zhou W, Jubb AM, Strickland L, Schmidt M, Duron SG, Campbell DA, Zheng W, Dehdashti S, Shen M, Yang N, ... ... Hoeflich KP, et al. Small molecule inhibition of group I p21-activated kinases in breast cancer induces apoptosis and potentiates the activity of microtubule stabilizing agents. Breast Cancer Research : Bcr. 17: 59. PMID 25902869 DOI: 10.1186/S13058-015-0564-5 |
0.274 |
|
| 2012 |
Crawford JJ, Hoeflich KP, Rudolph J. p21-Activated kinase inhibitors: a patent review. Expert Opinion On Therapeutic Patents. 22: 293-310. PMID 22404134 DOI: 10.1517/13543776.2012.668758 |
0.273 |
|
| 2014 |
Zhou W, Jubb AM, Lyle K, Xiao Q, Ong CC, Desai R, Fu L, Gnad F, Song Q, Haverty PM, Aust D, Grützmann R, Romero M, Totpal K, Neve RM, ... ... Hoeflich KP, et al. PAK1 mediates pancreatic cancer cell migration and resistance to MET inhibition. The Journal of Pathology. 234: 502-13. PMID 25074413 DOI: 10.1002/Path.4412 |
0.263 |
|
| 2012 |
Chow HY, Jubb AM, Koch JN, Jaffer ZM, Stepanova D, Campbell DA, Duron SG, O'Farrell M, Cai KQ, Klein-Szanto AJ, Gutkind JS, Hoeflich KP, Chernoff J. p21-Activated kinase 1 is required for efficient tumor formation and progression in a Ras-mediated skin cancer model. Cancer Research. 72: 5966-75. PMID 22983922 DOI: 10.1158/0008-5472.Can-12-2246 |
0.263 |
|
| 2006 |
Li GY, Zhang Y, Chan MC, Mal TK, Hoeflich KP, Inouye M, Ikura M. Characterization of dual substrate binding sites in the homodimeric structure of Escherichia coli mRNA interferase MazF. Journal of Molecular Biology. 357: 139-50. PMID 16413577 DOI: 10.1016/J.Jmb.2005.12.035 |
0.259 |
|
| 2016 |
Lee W, Crawford JJ, Aliagas I, Murray LJ, Tay S, Wang W, Heise CE, Hoeflich KP, La H, Mathieu S, Mintzer R, Ramaswamy S, Rouge L, Rudolph J. Synthesis and evaluation of a series of 4-azaindole-containing p21-activated kinase-1 inhibitors. Bioorganic & Medicinal Chemistry Letters. PMID 27346791 DOI: 10.1016/J.Bmcl.2016.06.031 |
0.257 |
|
| 2015 |
Gross S, Rahal R, Stransky N, Lengauer C, Hoeflich KP. Targeting cancer with kinase inhibitors. The Journal of Clinical Investigation. 125: 1780-9. PMID 25932675 DOI: 10.1172/JCI76094 |
0.253 |
|
| 2012 |
Ong CC, Jubb AM, Haverty PM, Zhou W, Harris AL, Belvin M, Friedman LS, Koeppen H, Hoeflich KP. Abstract B8: Targeting p21-activated kinases in human lung cancer Clinical Cancer Research. 18: B8-B8. DOI: 10.1158/1078-0432.12Aacriaslc-B8 |
0.25 |
|
| 2009 |
Hoeflich KP, O'Brien C, Boyd Z, Cavet G, Guerrero S, Jung K, Januario T, Savage H, Punnoose E, Truong T, Zhou W, Berry L, Murray L, Amler L, Belvin M, et al. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 4649-64. PMID 19567590 DOI: 10.1158/1078-0432.CCR-09-0317 |
0.249 |
|
| 2012 |
Wong H, Vernillet L, Peterson A, Ware JA, Lee L, Martini JF, Yu P, Li C, Del Rosario G, Choo EF, Hoeflich KP, Shi Y, Aftab BT, Aoyama R, Lam ST, et al. Bridging the gap between preclinical and clinical studies using pharmacokinetic-pharmacodynamic modeling: an analysis of GDC-0973, a MEK inhibitor. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 3090-9. PMID 22496205 DOI: 10.1158/1078-0432.CCR-12-0445 |
0.249 |
|
| 2013 |
Hatzivassiliou G, Haling JR, Chen H, Song K, Price S, Heald R, Hewitt JF, Zak M, Peck A, Orr C, Merchant M, Hoeflich KP, Chan J, Luoh SM, Anderson DJ, et al. Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers. Nature. 501: 232-6. PMID 23934108 DOI: 10.1038/Nature12441 |
0.246 |
|
| 2022 |
Wang X, Jiang L, Thao K, Sussman C, LaBranche T, Palmer M, Harris P, McKnight GS, Hoeflich K, Schalm S, Torres V. Protein Kinase A Downregulation Delays the Development and Progression of Polycystic Kidney Disease. Journal of the American Society of Nephrology : Jasn. PMID 35236775 DOI: 10.1681/ASN.2021081125 |
0.244 |
|
| 2016 |
Rudolph J, Murray LJ, Ndubaku CO, O'Brien T, Blackwood EM, Wang W, Aliagas I, Gazzard L, Crawford JJ, Drobnick J, Lee W, Zhao X, Hoeflich KP, Favor DA, Dong P, et al. Chemically diverse Group I p21-activated kinase (PAK) inhibitors impart acute cardiovascular toxicity with a narrow therapeutic window. Journal of Medicinal Chemistry. PMID 27167326 DOI: 10.1021/Acs.Jmedchem.6B00638 |
0.243 |
|
| 2015 |
Rudolph J, Crawford JJ, Hoeflich KP, Wang W. Inhibitors of p21-activated kinases (PAKs). Journal of Medicinal Chemistry. 58: 111-29. PMID 25415869 DOI: 10.1021/Jm501613Q |
0.242 |
|
| 2012 |
Hatzivassiliou G, Liu B, O'Brien C, Spoerke JM, Hoeflich KP, Haverty PM, Soriano R, Forrest WF, Heldens S, Chen H, Toy K, Ha C, Zhou W, Song K, Friedman LS, et al. ERK inhibition overcomes acquired resistance to MEK inhibitors. Molecular Cancer Therapeutics. 11: 1143-54. PMID 22402123 DOI: 10.1158/1535-7163.Mct-11-1010 |
0.242 |
|
| 2015 |
Rudolph J, Aliagas I, Crawford JJ, Mathieu S, Lee W, Chao Q, Dong P, Rouge L, Wang W, Heise C, Murray LJ, La H, Liu Y, Manning G, Diederich F, ... Hoeflich KP, et al. Leveraging the Pre-DFG Residue Thr-406 To Obtain High Kinase Selectivity in an Aminopyrazole-Type PAK1 Inhibitor Series. Acs Medicinal Chemistry Letters. 6: 711-5. PMID 26101579 DOI: 10.1021/Acsmedchemlett.5B00151 |
0.24 |
|
| 2009 |
Wong H, Belvin M, Herter S, Hoeflich KP, Murray LJ, Wong L, Choo EF. Pharmacodynamics of 2-[4-[(1E)-1-(hydroxyimino)-2,3-dihydro-1H-inden-5-yl]-3-(pyridine-4-yl)-1H-pyrazol-1-yl]ethan-1-ol (GDC-0879), a potent and selective B-Raf kinase inhibitor: understanding relationships between systemic concentrations, phosphorylated mitogen-activated protein kinase kinase 1 inhibition, and efficacy. The Journal of Pharmacology and Experimental Therapeutics. 329: 360-7. PMID 19147858 DOI: 10.1124/jpet.108.148189 |
0.236 |
|
| 2015 |
Radu M, Lyle K, Hoeflich KP, Villamar-Cruz O, Koeppen H, Chernoff J. p21-Activated Kinase 2 Regulates Endothelial Development and Function through the Bmk1/Erk5 Pathway. Molecular and Cellular Biology. 35: 3990-4005. PMID 26391956 DOI: 10.1128/Mcb.00630-15 |
0.218 |
|
| 2014 |
Staben ST, Feng JA, Lyle K, Belvin M, Boggs J, Burch JD, Chua CC, Cui H, DiPasquale AG, Friedman LS, Heise C, Koeppen H, Kotey A, Mintzer R, Oh A, ... ... Hoeflich KP, et al. Back pocket flexibility provides group II p21-activated kinase (PAK) selectivity for type I 1/2 kinase inhibitors. Journal of Medicinal Chemistry. 57: 1033-45. PMID 24432870 DOI: 10.1021/Jm401768T |
0.217 |
|
| 2015 |
Ndubaku CO, Crawford JJ, Drobnick J, Aliagas I, Campbell D, Dong P, Dornan LM, Duron S, Epler J, Gazzard L, Heise CE, Hoeflich KP, Jakubiak D, La H, Lee W, et al. Design of Selective PAK1 Inhibitor G-5555: Improving Properties by Employing an Unorthodox Low-pK a Polar Moiety. Acs Medicinal Chemistry Letters. 6: 1241-6. PMID 26713112 DOI: 10.1021/Acsmedchemlett.5B00398 |
0.216 |
|
| 2012 |
Wallin JJ, Guan J, Edgar KA, Zhou W, Francis R, Torres AC, Haverty PM, Eastham-Anderson J, Arena S, Bardelli A, Griffin S, Goodall JE, Grimshaw KM, Hoeflich KP, Torrance C, et al. Active PI3K pathway causes an invasive phenotype which can be reversed or promoted by blocking the pathway at divergent nodes. Plos One. 7: e36402. PMID 22570710 DOI: 10.1371/Journal.Pone.0036402 |
0.204 |
|
| 2006 |
Hoeflich KP, Gray DC, Eby MT, Tien JY, Wong L, Bower J, Gogineni A, Zha J, Cole MJ, Stern HM, Murray LJ, Davis DP, Seshagiri S. Oncogenic BRAF is required for tumor growth and maintenance in melanoma models. Cancer Research. 66: 999-1006. PMID 16424035 DOI: 10.1158/0008-5472.Can-05-2720 |
0.202 |
|
| 2013 |
Gnad F, Young A, Zhou W, Lyle K, Ong CC, Stokes MP, Silva JC, Belvin M, Friedman LS, Koeppen H, Minden A, Hoeflich KP. Systems-wide analysis of K-Ras, Cdc42, and PAK4 signaling by quantitative phosphoproteomics. Molecular & Cellular Proteomics : McP. 12: 2070-80. PMID 23608596 DOI: 10.1074/mcp.M112.027052 |
0.192 |
|
| 2011 |
Choo EF, Belvin M, Chan J, Hoeflich K, Orr C, Robarge K, Yang X, Zak M, Boggs J. Preclinical disposition and pharmacokinetics-pharmacodynamic modeling of biomarker response and tumour growth inhibition in xenograft mouse models of G-573, a MEK inhibitor. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 40: 751-62. PMID 20836753 DOI: 10.3109/00498254.2010.514365 |
0.192 |
|
| 2008 |
Shang Y, Mao Y, Batson J, Scales SJ, Phillips G, Lackner MR, Totpal K, Williams S, Yang J, Tang Z, Modrusan Z, Tan C, Liang WC, Tsai SP, Vanderbilt A, ... ... Hoeflich K, et al. Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptake. Molecular Cancer Therapeutics. 7: 2599-608. PMID 18790743 DOI: 10.1158/1535-7163.Mct-07-2401 |
0.191 |
|
| 2009 |
Yao E, Zhou W, Lee-Hoeflich ST, Truong T, Haverty PM, Eastham-Anderson J, Lewin-Koh N, Gunter B, Belvin M, Murray LJ, Friedman LS, Sliwkowski MX, Hoeflich KP. Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 4147-56. PMID 19509167 DOI: 10.1158/1078-0432.Ccr-08-2814 |
0.186 |
|
| 2016 |
Hoeflich KP, Guan J, Edgar KA, O'Brien C, Savage H, Wilson TR, Neve RM, Friedman LS, Wallin JJ. The PI3K inhibitor taselisib overcomes letrozole resistance in a breast cancer model expressing aromatase. Genes & Cancer. 7: 73-85. PMID 27382432 DOI: 10.18632/genesandcancer.100 |
0.177 |
|
| 2008 |
Lee-Hoeflich ST, Crocker L, Yao E, Pham T, Munroe X, Hoeflich KP, Sliwkowski MX, Stern HM. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Research. 68: 5878-87. PMID 18632642 DOI: 10.1158/0008-5472.CAN-08-0380 |
0.177 |
|
| 2015 |
Crawford JJ, Lee W, Aliagas I, Mathieu S, Hoeflich KP, Zhou W, Wang W, Rouge L, Murray L, La H, Liu N, Fan PW, Cheong J, Heise CE, Ramaswamy S, et al. Structure-Guided Design of Group I Selective p21-Activated Kinase Inhibitors. Journal of Medicinal Chemistry. 58: 5121-36. PMID 26030457 DOI: 10.1021/Acs.Jmedchem.5B00572 |
0.177 |
|
| 2012 |
Choo EF, Belvin M, Boggs J, Deng Y, Hoeflich KP, Ly J, Merchant M, Orr C, Plise E, Robarge K, Martini JF, Kassees R, Aoyama RG, Ramaiya A, Johnston SH. Preclinical disposition of GDC-0973 and prospective and retrospective analysis of human dose and efficacy predictions. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 40: 919-27. PMID 22315332 DOI: 10.1124/dmd.111.043778 |
0.176 |
|
| 2010 |
Belvin M, Berry L, Chan J, den Otter D, Friedman L, Hoeflich K, Koeppen H, Merchant M, Orr C, Rice K. 132 Intermittent dosing of the MEK inhibitor, GDC-0973, and the PI3K inhibitor, GDC-0941, results in prolonged accumulation of Bim and causes strong tumor growth inhibition in vivo European Journal of Cancer Supplements. 8: 48. DOI: 10.1016/S1359-6349(10)71837-1 |
0.169 |
|
| 2013 |
Arias-Romero LE, Villamar-Cruz O, Huang M, Hoeflich KP, Chernoff J. Pak1 kinase links ErbB2 to β-catenin in transformation of breast epithelial cells. Cancer Research. 73: 3671-82. PMID 23576562 DOI: 10.1158/0008-5472.Can-12-4453 |
0.166 |
|
| 2010 |
Belvin M, Berry L, Chan J, Hoeflich K, Liu B, Malek S, Merchant M, Orr C, Song K, Hatzivassiliou G. 205 Distinct inhibitory properties of MEK inhibitors on pathway feedback translate into differential potency in BRAF and RAS mutant cancer cells European Journal of Cancer Supplements. 8: 68. DOI: 10.1016/S1359-6349(10)71910-8 |
0.162 |
|
| 2015 |
Junttila MR, Devasthali V, Cheng JH, Castillo J, Metcalfe C, Clermont AC, Otter DD, Chan E, Bou-Reslan H, Cao T, Forrest W, Nannini MA, French D, Carano R, Merchant M, ... Hoeflich KP, et al. Modeling targeted inhibition of MEK and PI3 kinase in human pancreatic cancer. Molecular Cancer Therapeutics. 14: 40-7. PMID 25376606 DOI: 10.1158/1535-7163.MCT-14-0030 |
0.153 |
|
| 2006 |
Hoeflich KP, Truong K, Ikura M. Ca2+ as a second messenger: New reporters for calcium (cameleons and camgaroos) Cell Biology, Four-Volume Set. 2: 307-315. DOI: 10.1016/B978-012164730-8/50112-X |
0.152 |
|
| 2019 |
Hatlen MA, Schmidt-Kittler O, Sherwin CA, Rozsahegyi E, Rubin N, Sheets MP, Kim JL, Miduturu C, Bifulco N, Brooijmans N, Shi H, Guzi T, Boral A, Lengauer C, Dorsch M, ... ... Hoeflich KP, et al. Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma. Cancer Discovery. PMID 31575540 DOI: 10.1158/2159-8290.CD-19-0367 |
0.15 |
|
| 2015 |
Hoeflich K, Hagel M, Miduturu C, Sheets M, Rubin N, Weng W, Stransky N, Bifulco N, Kim J, Hodous B, Brooijmans N, Shutes A, Winter C, Lengauer C, Kohl N, et al. O048 : First selective small molecule inhibitor of FGFR4 for the treatment of hepatocellular carcinomas with an activated FGFR4 signaling pathway Journal of Hepatology. 62: S215-S216. DOI: 10.1016/S0168-8278(15)30062-3 |
0.149 |
|
| 2012 |
Hatzivassiliou G, Haling J, Chen H, Song K, Peck A, Hoeflich K, Friedman L, Malek S, Belvin M. 378 Differential Targeting of KRAS and BRAF Mutant Tumors Using MEK Inhibitors with Distinct Mechanisms of Action European Journal of Cancer. 48: 115. DOI: 10.1016/S0959-8049(12)72176-7 |
0.141 |
|
| 2010 |
Friedman L, Belvin M, Berry L, Haverty P, Hoeflich K, Lackner M, Sampath D, Wallin J, Yauch B. 142 GDC-0941 PI3K inhibitor activity in preclinical lung cancer models European Journal of Cancer Supplements. 8: 51. DOI: 10.1016/S1359-6349(10)71847-4 |
0.129 |
|
| 2013 |
Hatzivassiliou G, Haling JR, Chen H, Song K, Price S, Heald R, Hewitt JFM, Zak M, Peck A, Orr C, Merchant M, Hoeflich KP, Chan J, Luoh S, Anderson DJ, et al. Erratum: Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers Nature. 502: 258-258. DOI: 10.1038/nature12659 |
0.114 |
|
| 2011 |
Lee-Hoeflich ST, Pham TQ, Dowbenko D, Munroe X, Lee J, Li L, Zhou W, Haverty PM, Pujara K, Stinson J, Chan SM, Eastham-Anderson J, Pandita A, Seshagiri S, Hoeflich KP, et al. PPM1H is a p27 phosphatase implicated in trastuzumab resistance. Cancer Discovery. 1: 326-37. PMID 22586611 DOI: 10.1158/2159-8290.Cd-11-0062 |
0.112 |
|
| 2008 |
Hoeflich KP, Jaiswal B, Davis DP, Seshagiri S. Inducible BRAF suppression models for melanoma tumorigenesis. Methods in Enzymology. 439: 25-38. PMID 18374154 DOI: 10.1016/S0076-6879(07)00403-X |
0.107 |
|
| 2017 |
Yoo C, Kang J, Kim D, Kim KP, Ryoo BY, Hong SM, Hwang JJ, Jeong SY, Hwang S, Kim KH, Lee YJ, Hoeflich KP, Schmidt-Kittler O, Miller S, Choi EK. Multiplexed gene expression profiling identifies the FGFR4 pathway as a novel biomarker in intrahepatic cholangiocarcinoma. Oncotarget. PMID 28445152 DOI: 10.18632/Oncotarget.16951 |
0.104 |
|
| 2012 |
Baudy AR, Dogan T, Flores-Mercado JE, Hoeflich KP, Su F, van Bruggen N, Williams SP. FDG-PET is a good biomarker of both early response and acquired resistance in BRAFV600 mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973. Ejnmmi Research. 2: 22. PMID 22651703 DOI: 10.1186/2191-219X-2-22 |
0.1 |
|
| 2009 |
Jaiswal BS, Janakiraman V, Kljavin NM, Eastham-Anderson J, Cupp JE, Liang Y, Davis DP, Hoeflich KP, Seshagiri S. Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors. Plos One. 4: e5717. PMID 19492075 DOI: 10.1371/journal.pone.0005717 |
0.098 |
|
| 2007 |
Gray DC, Hoeflich KP, Peng L, Gu Z, Gogineni A, Murray LJ, Eby M, Kljavin N, Seshagiri S, Cole MJ, Davis DP. pHUSH: a single vector system for conditional gene expression. Bmc Biotechnology. 7: 61. PMID 17897455 DOI: 10.1186/1472-6750-7-61 |
0.086 |
|
| 2015 |
Ndubaku CO, Crawford JJ, Drobnick J, Aliagas I, Campbell D, Dong P, Dornan LM, Duron S, Epler J, Gazzard L, Heise CE, Hoeflich KP, Jakubiak D, La H, Lee W, et al. Design of Selective PAK1 Inhibitor G-5555: Improving Properties by Employing an Unorthodox Low-pKa Polar Moiety Acs Medicinal Chemistry Letters. 6: 1241-1246. DOI: 10.1021/acsmedchemlett.5b00398 |
0.083 |
|
| 2012 |
Liu J, Lee W, Jiang Z, Chen Z, Jhunjhunwala S, Haverty PM, Gnad F, Guan Y, Gilbert HN, Stinson J, Klijn C, Guillory J, Bhatt D, Vartanian S, Walter K, ... ... Hoeflich KP, et al. Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events. Genome Research. 22: 2315-27. PMID 23033341 DOI: 10.1101/Gr.140988.112 |
0.073 |
|
| 2019 |
Kim RD, Sarker D, Meyer T, Yau T, Macarulla T, Park JW, Choo SP, Hollebecque A, Sung MW, Lim HY, Mazzaferro V, Trojan J, Zhu AX, Yoon JH, Sharma S, ... ... Hoeflich KP, et al. First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant Fibroblast Growth Factor 19 Signaling as a Driver Event in Hepatocellular Carcinoma. Cancer Discovery. PMID 31575541 DOI: 10.1158/2159-8290.CD-19-0555 |
0.066 |
|
| 2011 |
Jubb AM, Hoeflich KP, Haverty PM, Wang J, Koeppen H. Ascl2 and 11p15.5 amplification in colorectal cancer. Gut. 60: 1606-7; author reply. PMID 21106550 DOI: 10.1136/Gut.2010.231746 |
0.033 |
|
| Hide low-probability matches. |